BioAtla Announces Share Consolidation

Core Viewpoint - BioAtla, Inc. is implementing a 50-for-1 share consolidation to increase its stock price and regain compliance with Nasdaq's minimum bid price requirement of $1.00, effective April 6, 2026 [1][2]. Company Actions - The share consolidation will convert every fifty shares of common stock into one share, with no fractional shares issued; stockholders entitled to fractional shares will receive cash equivalent [4]. - The consolidation was approved by stockholders at a special meeting on March 23, 2026, as part of a merger agreement with its wholly-owned subsidiary, BA Merger Sub, Inc. [3]. Impact on Stock and Options - Following the consolidation, the number of shares available under the company's equity incentive plan and employee stock purchase plan will be proportionately reduced, and adjustments will be made to the exercise prices and number of shares for outstanding stock options and warrants [5]. Stockholder Information - Stockholders holding shares electronically will not need to take action to receive post-consolidation shares, while those with shares through brokers will have their positions automatically adjusted [6]. Company Overview - BioAtla is a clinical-stage biotechnology company focused on developing Conditionally Active Biologic (CAB) antibody therapeutics for solid tumors, with a robust pipeline including ADCs and T cell engagers [7]. - The company has over 780 active patent matters, with more than 500 issued patents, covering its CAB platform technology and products [7]. Clinical Pipeline - BioAtla's clinical pipeline includes Ozuriftamab vedotin (CAB-ROR2-ADC) in Phase 3 for OPSCC and Mecbotamab vedotin (CAB-AXL-ADC) in Phase 2 for multiple solid tumor indications [8][13]. - The company is also developing BA3182, a bispecific T cell engager antibody, currently in Phase 1 for advanced adenocarcinoma [10]. Market Opportunity - Ozuriftamab vedotin targets a market opportunity exceeding $7 billion worldwide, particularly for HPV+ cancers, and has received Fast Track Designation from the FDA for treating recurrent or metastatic squamous cell carcinoma of the head and neck [11].